3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
41
Non-Muscle Invasive Bladder Neoplasms
25
Colorectal Neoplasms
20
Anus Neoplasms
17
Carcinoma, Transitional Cell
15
Neoplasm Metastasis
12
Carcinoma, Hepatocellular
10
Appendiceal Neoplasms
10
Stomach Neoplasms
9
Peritoneal Neoplasms
9
Pancreatic Neoplasms
8
Carcinoma, Non-Small-Cell Lung
7
Neoplasms
6
Lung Neoplasms
6
Colonic Neoplasms
6
Rectal Neoplasms
5
Liver Neoplasms
5
Sarcoma
4
Anal Canal Carcinoma
4
Urologic Neoplasms
3
Urologic Diseases
3
Urinary Bladder Diseases
3
Pseudomyxoma Peritonei
3
Mesothelioma, Malignant
3
Gastrointestinal Neoplasms
3
Carcinoma in Situ
3
Carcinoma
3
Breast Neoplasms
3
Urogenital Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Interventions
Radiotherapy
3
Cisplatin
3
Fluorouracil
2
tislelizumab
1
pembrolizumab
1
motexafin gadolinium
1
Tamoxifen
1
Talaporfin
1
TP protocol
1
Spinal Puncture
1
Rhenium
1
Radiosurgery
1
Poly I-C
1
Paclitaxel
1
Oxaliplatin
1
Mitomycin
1
Lomustine
1
Irinotecan
1
Gemcitabine
1
Folfox protocol
1
Ethiodized Oil
1
Erlotinib Hydrochloride
1
Docetaxel
1
Cetuximab
1
Carboplatin
1
Blood Specimen Collection
1
Bevacizumab
1
Anesthesia, General
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasm Recurrence, Local
×
Mitomycin
×
Clear all
NCT01200992
2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3
Terminated
84 enrolled
7 charts